Authors: Falgueyret, JP Oballa, RM Okamoto, O Wesolowski, G Aubin, Y Rydzewski, RM Prasit, P Riendeau, D Rodan, SB Percival, MD

Citation: Jp. Falgueyret et al., Novel, nonpeptidic cyanamides as potent and reversible inhibitors of humancathepsins K and L, J MED CHEM, 44(1), 2001, pp. 94-104

Authors: Duggan, ME Duong, LT Fisher, JE Hamill, TG Hoffman, WF Huff, JR Ihle, NC Leu, CT Nagy, RM Perkins, JJ Rodan, SB Wesolowski, G Whitman, DB Zartman, AE Rodan, GA Hartman, GD

Citation: Me. Duggan et al., Nonpeptide alpha(v)beta(3) antagonists. 1. Transformation of a potent, integrin-selective alpha(IIb)beta(3) antagonist into a potent alpha(v)beta(3) antagonist, J MED CHEM, 43(20), 2000, pp. 3736-3745

Authors: Fisher, JE Rogers, MJ Halasy, JM Luckman, SP Hughes, DE Masarachia, PJ Wesolowski, G Russell, RGG Rodan, GA Reszka, AA

Citation: Je. Fisher et al., Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro, P NAS US, 96(1), 1999, pp. 133-138

Authors: Lafage-Proust, MH Wesolowski, G Ernst, M Rodan, GA Rodan, SB

Citation: Mh. Lafage-proust et al., Retinoic acid effects on an SV-40 large T antigen immortalized adult rat bone cell line, J CELL PHYS, 179(3), 1999, pp. 267-275